EFM
IOVA icon

E Fund Management’s Iovance Biotherapeutics IOVA Stock Holding History

E Fund Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
56,806
+2,377
+4% +$9.03K 0.01% 427
2026
Q1 		$191K Buy
+54,429
New +$174K 0.01% 452
2025
Q2 		$56K Sell
32,559
-6,835
-17% -$17K ﹤0.01% 388
2025
Q1 		$131K Sell
39,394
-45
-0.1% -$232 0.01% 374
2024
Q4 		$292K Sell
39,439
-2,513
-6% -$23.3K 0.01% 319
2024
Q3 		$394K Buy
41,952
+1,040
+3% +$9.85K 0.02% 224
2024
Q2 		$328K Buy
40,912
+13,310
+48% +$143K 0.02% 220
2024
Q1 		$409K Sell
27,602
-39,136
-59% -$456K 0.03% 212
2023
Q4 		$543K Sell
66,738
-10,112
-13% -$52.9K 0.03% 145
2023
Q3 		$350K Buy
76,850
+20,241
+36% +$132K 0.03% 190
2023
Q2 		$399K Sell
56,609
-5,579
-9% -$39.9K 0.03% 170
2023
Q1 		$380K Buy
62,188
+1,236
+2% +$8.53K 0.03% 183
2022
Q4 		$389K Buy
60,952
+18,421
+43% +$144K 0.03% 189
2022
Q3 		$407K Sell
42,531
-10,224
-19% -$118K 0.04% 180
2022
Q2 		$582K Buy
52,755
+32,402
+159% +$425K 0.05% 121
2022
Q1 		$339K Buy
+20,353
New +$315K 0.01% 171

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

E Fund Management's IOVA Position: Q2 2026 in Review

E Fund Management increased its Iovance Biotherapeutics (IOVA) stake by 4.4% in Q2 2026, buying an estimated $9.03K and bringing the position to 56,806 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #427.

E Fund Management first reported a position in IOVA in Q1 2022 and has held it in 16 quarters since. The position peaked at $582K in Q2 2022. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • E Fund Management held 56,806 shares of Iovance Biotherapeutics worth $236K as of Q2 2026.
  • E Fund Management bought 2,377 Iovance Biotherapeutics shares in Q2 2026, an estimated $9.03K.
  • Iovance Biotherapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #427 holding.
  • E Fund Management first reported a position in Iovance Biotherapeutics in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's Iovance Biotherapeutics position peaked at $582K in Q2 2022.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.